Breakthrough Turnaround Time for Human Genome Sequencing, Powered by HiSeq 2500®
SAN DIEGO--(BUSINESS WIRE)--Jun. 20, 2012-- Illumina, Inc. (NASDAQ: ILMN) today launched the RapidTrack Whole Genome Sequencing Service (RapidTrack WGS), a new offering in its FastTrack Sequencing Services operation that delivers a whole human genome in less than two weeks. The premium service offers the fastest sample-to-data turnaround time of any whole human genome sequencing service available today.
RapidTrack WGS utilizes Illumina’s new HiSeq 2500 sequencing system, which is capable of sequencing a complete human genome in one day. In combination with an accelerated sample preparation protocol and the Company’s new iSAAC genome alignment software, sample-to-data cycle time for a complete human genome is five days with the new service. To allow for queue time, RapidTrack WGS guarantees a turnaround of less than 14 days.
“Earlier this year, we previewed the rapid turn-around sequencing capabilities of the HiSeq 2500 system. Today, we are pleased to offer researchers access to the platform’s capabilities through RapidTrack WGS and our FastTrack Services,” said Jay Flatley, President and Chief Executive Officer of Illumina. “Additionally, we will shortly validate the HiSeq 2500 in our CLIA laboratory allowing fast response clinical sequencing. The processes and logistics established for our FastTrack research customers will ensure robust, high-quality results for the emerging clinical opportunity.”
By incorporating HiSeq 2500 into its Services operation, Illumina is deploying the capability to sequence a human genome in a day with unsurpassed data quality (>80% Q30 data) and the lowest sample input (3 μg) of any whole-genome sequencing service. RapidTrack WGS will deliver a full data set of all SNPs, indels, and structural variants in an industry-standard data format.
As a test of this novel capability, Illumina recently ran two test samples in conjunction with the Translational Genomics Research Institute (TGen). The samples were received on a Tuesday, and data for both samples were returned on the following Tuesday.
According to David W. Craig, Ph.D. and Matthew J. Huentelman Ph.D., co-directors of the Center for Rare Childhood Disorders at TGen, “We were pleased to see that the data quality was similar to what we have come to expect from the Illumina sequencers in our own laboratories. In fact, the scientists within our Center for Rare Childhood Disorders were able to identify mutations that are the likely genetic cause of one sequenced individual’s disorder, within 48 hours of receiving processed data from Illumina and less than 2 weeks from shipping DNA to the Company. We anticipate that this shortened timeline for sequencing and data processing, when accompanied by validation in a CLIA-certified laboratory, will substantially accelerate our ability to translate genomics research to the clinic in a timely manner.”
Dr. Craig added, “Illumina’s new RapidTrack Whole Genome Sequencing Service will substantially free up time and funds, improving our ability to focus on the development of new treatment paradigms that could extend and improve the quality of life of patients.”
RapidTrack WGS is available today at a price of $9,500 per sample for individual samples, with volume discounts to $7,600 for commitments of 50 or more samples. Initially, the service capacity will be 5‒10 whole human genomes per week, and capacity will ramp as demand requires.
Illumina’s FastTrack Services combine the Company’s high performance platforms with expert Illumina scientists, delivering high-quality sequencing and genotyping data to support research projects. For more information about FastTrack Services, go to www.illumina.com/services.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Kevin Williams, MD
Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-882-6822
pr@illumina.com
